MedPath

General Anesthesia Versus Sedation By Dexmedetomidine and Ketamine With Local Infiltration for Percutaneous Transcatheter Closure of Atrial Septal Defect in Pediatric Patients

Not Applicable
Recruiting
Conditions
Local Infiltration
General Anesthesia
Dexmedetomidine
Ketamine
Atrial Septal Defect
Registration Number
NCT06431178
Lead Sponsor
Tanta University
Brief Summary

The aim of the present study is to compare between general anesthesia versus sedation with dexmedetomidine and ketamine with local infilteration at the catheter insertion site in pediatric patients undergoing transcutaneous closure of atrial septal defect on hemodynamic changes.

Detailed Description

Atrial septal defect (ASD) is one of the most common types of congenital heart defects, occurring in about 25% of children General anaesthesia is usually obtained with tracheal intubation and mechanical ventilation or spontaneous breathing, the depth of anesthesia required to tolerate the presence of a tracheal tube will invariably lead to some reduction in myocardial contractility and alteration of respiratory mechanics. The goal of anesthetic technique is to provide sedation and analgesia during cardiac catheterization to ensure immobility and hemodynamic stability.

Ketamine is an N-methyl-D-aspartate receptor (NMDA) antagonist with sedative, analgesic, and sympathomimetic effects. Among its benefits ,it has the ability to protect airway reflexes with minimal effect on ventilatory drive.

Dexmedetomidine is a highly selective alpha-2 adrenoreceptor agonist with sedative, anxiolytic, and analgesic effect, it also blunts the sympathetic nervous system response to surgical stimulation.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Aged 3-8 years old.
  • Both genders.
  • American Society of Anesthesiologists (ASA) physical status II-III
  • Pediatric patients scheduled for elective transcatheter atrial septal defect closure.
Exclusion Criteria
  • Patients with multiple congenital anomalies.
  • Patients with congestive heart failure
  • Patients with Organ dysfunction liver or renal disease or pulmonary disease.
  • Recent chest infection.
  • Airway abnormalities.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Heart rateImmediately after the intervention

Heart rate will be measured at baseline, after induction ,10 min after catheter insertion site,30 min during procedure and post emergence in both groups.

Secondary Outcome Measures
NameTimeMethod
Lengh of hospital stay28 days postoperative

Length of hospital stay will be measured from admission till discharge from hospital

Recovery timeImmediately after discharge from post-anesthesia care unit

Recovery time will be measured from the end of surgery till discharge from post-anesthesia care unit (PACU).

Complications24 hours postoperative

Postoperative complications such as arrythmia, hypotension, bradycardia, nausea and vomiting will be measured.

O2 saturationImmediately after the intervention

O2 saturation will be measured at baseline, after induction ,10 min after catheter insertion site,30 min during procedure and post emergence in both groups.

Mean arterial blood pressureImmediately after the intervention

Mean arterial blood pressure will be measured at baseline, after induction ,10 min after catheter insertion site,30 min during procedure and post emergence in both groups.

Respiratory rateImmediately after the intervention

Respiratory rate will be measured at baseline, after induction ,10 min after catheter insertion site,30 min during procedure and post emergence in both groups.

Trial Locations

Locations (1)

Aya Ebrahim Abdelhafez Mashal

🇪🇬

Tanta, El-Gharbia Governorate, Egypt, Egypt

Aya Ebrahim Abdelhafez Mashal
🇪🇬Tanta, El-Gharbia Governorate, Egypt, Egypt
Aya E Mashal, Master
Contact
00201009167298
ayaebrahim406@gmail.com
Mohammad E Okab, MD
Sub Investigator
Aymen A Abd Elmaksoud Yousef, MD
Sub Investigator
Jehan M Darwish, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.